[{"id":"f19011bc-a0f1-46bf-8979-e38379c2fbd2","acronym":"NEO-COMBATXL","url":"https://clinicaltrials.gov/study/NCT06902376","created_at":"2025-06-07T14:40:06.805Z","updated_at":"2025-06-07T14:40:06.805Z","phase":"Phase 1","brief_title":"XL092 and Cemiplimab in BRAF WT Thyroid Cancer","source_id_and_acronym":"NCT06902376 - NEO-COMBATXL","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • zanzalintinib (XL092)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/03/2025","start_date":" 06/03/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-06-04"},{"id":"80d8b063-fde0-450d-9857-f3e96ed43e05","acronym":"STELLAR-305","url":"https://clinicaltrials.gov/study/NCT06082167","created_at":"2023-10-14T01:13:13.670Z","updated_at":"2025-02-25T16:19:12.483Z","phase":"Phase 2/3","brief_title":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06082167 - STELLAR-305","lead_sponsor":"Exelixis","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • zanzalintinib (XL092)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 06/07/2024","start_date":" 06/07/2024","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-01-31"},{"id":"3e93e97f-f870-4d69-bd14-6657626fe0db","acronym":"STELLAR-303","url":"https://clinicaltrials.gov/study/NCT05425940","created_at":"2022-06-21T23:54:39.625Z","updated_at":"2024-07-02T16:35:14.190Z","phase":"Phase 3","brief_title":"Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05425940 - STELLAR-303","lead_sponsor":"Exelixis","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR • RAS mutation","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Stivarga (regorafenib) • zanzalintinib (XL092)"],"overall_status":"Recruiting","enrollment":" Enrollment 874","initiation":"Initiation: 09/07/2022","start_date":" 09/07/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-03-19"},{"id":"e993ce91-2679-4a51-a9c2-2a1e49731991","acronym":"","url":"https://clinicaltrials.gov/study/NCT03845166","created_at":"2021-01-18T18:59:01.227Z","updated_at":"2024-07-02T16:35:18.886Z","phase":"Phase 1","brief_title":"A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors","source_id_and_acronym":"NCT03845166","lead_sponsor":"Exelixis","biomarkers":" HER-2 • KRAS • BRAF • NRAS • MSI","pipe":" | ","alterations":" BRAF V600E • HR positive • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type","tags":["HER-2 • KRAS • BRAF • NRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • HR positive • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Bavencio (avelumab) • zanzalintinib (XL092)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 325","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-02-19"},{"id":"fa153fa1-88be-494d-a000-63ab41769eb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00454194","created_at":"2021-01-18T01:36:36.230Z","updated_at":"2024-07-02T16:37:24.233Z","phase":"Phase 2","brief_title":"Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT00454194","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" FLT1","pipe":"","alterations":" ","tags":["FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 09/01/2007","start_date":" 09/01/2007","primary_txt":" Primary completion: 07/01/2010","primary_completion_date":" 07/01/2010","study_txt":" Completion: 05/01/2013","study_completion_date":" 05/01/2013","last_update_posted":"2017-03-21"}]